[August 25, 2014] |
|
BIOLASE Creates Global Commercialization Team
IRVINE, Calif. --(Business Wire)--
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and
distributor of dental lasers, today announced that as part of its
ongoing transformation it has created a new Global Commercialization
Team and has hired two seasoned executives to lead its worldwide sales
and marketing organizations. Clark Barousse has been named Senior Vice
President for Worldwide Sales and Account Management, and Orlando P.
Rodrigues has been named Vice President and Chief Marketing Officer.
"The transformation of Biolase that is underway requires the entire
organization to build a single-minded competency focused on dental and
medical practitioners and their patients in order to deliver a
best-in-class experience," said Jeffrey M. Nugent, Board Member and
Acting Chief Executive Officer. "I'm confident that these changes, and
our new Global Commercialization Team, will help drive our growth and
turnaround strategy.
Mr. Barousse was most recently President of Hybridge, a network of
dental practices that works with clinicians to improve their practices,
where he helped drive revenue growth at dental centers. From 2008
through 2012, he served as the Senior Vice President of Global Sales and
Marketing for Biohorizons, and more than doubled sales from $45 million
in 2008 to $100 million in 2012, while reversing an $8 million loss into
a $20 million operating profit over the same time frame.
Prior to Biohorizons, Mr. Barousse was Vice President of Global
Marketing, Professional Affairs and Business Development for Smith &
Nephew Orthopedics from 2006-2008. From 2002 through 2005 he worked in
the Johnson & Johnson subsidiary, Ethicon, Inc., where he was
sequentially the Group Director, Global Marketing and Director of
Marketing for Biosurgical Discovery, where he instituted a voice of the
customer (VOC) initiative, and later Vice President of Biosurgical
Research and Development.
In his new role, Mr. Barousse will be responsible for Biolase's customer
acquisition and customer retention through stronger account management
and customer care.
"I believe my background and the Biolase product offering are an
exceptional fit," said Mr. Barousse. "I'll be drawing on my dental
practice growth experience, as well as my experiences in sales,
marketing and R&D roles at Biohorizons, Smith & Nephew Orthopedics,
Ethicon and Genzyme as I lead the Biolase sales team."
Mr. Rodrigues, was Vice President of Marketing for I-Flow Corporation
from 2002-2010, during which time revenues grew six fold. He created
brand awareness and marketing campaigns that motivated surgeons and
anesthesiologists to adopt I-Flow's ON-Q post-surgical pain relief
product as the standard of care. By the time I-Flow was acquired by
Kimberly Clark (News - Alert) in November 2009 for $325 million, it had a sales force
of approximately 300 individuals in 170 sales territories.
Previously, Mr. Rodrigues was Vice President of Marketing for Laser
Diagnostic Technologies, Inc., a laser medical device company serving
ophthalmologists and optometrists.
"I'm excited to return to Biolase, a company where dental and medical
market opportunities coexist," said Mr. Rodrigues. "Biolase has market
leading dental products and clinically significant technologies with
practice-enhancing benefits that have been under-marketed to dae. We
will work hard to ensure that our customers, prospective customers, and
patients understand the benefits and value that Waterlase® and other
Biolase products uniquely provide them."
About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical device company that develops,
manufactures, and markets innovative lasers in dentistry and medicine
and also markets and distributes high-end 2D and 3D digital imaging
equipment, CAD/CAM intraoral scanners, and in-office milling
machines and 3D printers. BIOLASE's products are focused on technologies
that advance the practice of dentistry and medicine
and offer benefits and value to healthcare professionals and their
patients. The Company's proprietary laser products incorporate
approximately 300 patented and patent-pending technologies designed to
provide biologically clinically superior performance with less pain and
faster recovery times. Its innovative products provide cutting-edge
technology at competitive prices to deliver the best results for
dentists and patients. BIOLASE's principal products
are revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical applications,
and a full line of dental imaging equipment. BIOLASE has sold more than
26,000 laser systems. Laser products under development address the
Company's core dental market and other adjacent medical and consumer
markets.
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at www.biolase.com,
Facebook at www.facebook.com/biolase,
Twitter (News - Alert) at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase,
LinkedIn (News - Alert) at www.linkedin.com/company/biolase,
Google (News - Alert)+ at www.google.com/+BIOLASEIrvine,
Instagram at www.instagram.com/biolaseinc,
and YouTube at www.youtube.com/biolasevideos.
BIOLASE® and WaterLase® are registered trademarks
of BIOLASE, Inc.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's
estimated or anticipated future results or other non-historical facts
are forward-looking statements, as are any statements in this press
release concerning prospects related to BIOLASE's strategic initiatives
and anticipated financial performance. Forward-looking statements can
also be identified through the use of words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates," "may,"
"will," and variations of these words or similar expressions. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which reflect BIOLASE's current perspective of existing
trends and information and speak only as of the date of this release.
Actual results may differ materially from BIOLASE's current expectations
depending upon a number of factors affecting BIOLASE's business. These
factors include, among others, adverse changes in general economic and
market conditions, competitive factors including but not limited to
pricing pressures and new product introductions, uncertainty of customer
acceptance of new product offerings and market changes, risks associated
with managing the growth of the business, and those other risks and
uncertainties that may be detailed, from time-to-time, in BIOLASE's
reports filed with the SEC (News - Alert). BIOLASE does not undertake any
responsibility to revise or update any forward-looking statements
contained herein.
[ Back To Homepage ]
|